CENTERSTONE is the first worldwide phase III trial that shows how effective an antiviral medication is at slowing the spread of a respiratory virus.
AbbVie declared that they had submitted the Biologics License Application (BLA) for trenibotulinumtoxinE (TrenibotE) to the United States FDA for the treatment of moderate to severe glabellar lines. [Read More…]
More than 12,000 new jobs will be created by investments, including 1,000 at Roche and more than 11,000 to support the development of new manufacturing capabilities in the US.
The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
Columvi therapy provides a much-needed, off-the-shelf, fixed-duration alternative for transplant ineligible individuals.
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
Lecanemab is the only approved Aβ monoclonal antibody that binds and clears hazardous protofibrils.
All nine subjects of phase 1 injected without any serious adverse events.
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
